Effect of a New Cohesive Ophthalmic Viscosurgical Device on Corneal Protection and Intraocular Pressure in Small-incision Cataract Surgery
Overview
Authors
Affiliations
Purpose: To compare the corneal protective and intraocular pressure (IOP) effects of a new cohesive ophthalmic viscosurgical (OVD), Neocrom Cohesive (sodium hyaluronate 1.4%), with those of Healon (sodium hyaluronate 1.0%) in cataract surgery.
Setting: Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.
Methods: This randomized patient-masked examiner-masked study with fellow-eye comparison comprised 29 cataract surgery patients. Surgery was performed with Neocrom Cohesive in 1 eye and Healon in the other eye. Central corneal thickness (CCT) was measured preoperatively and 1 day and 3 months postoperatively; endothelial cell density (ECD), preoperatively and 3 months postoperatively; and IOP, preoperatively and 6 hours and 1 day postoperatively.
Results: The mean CCT change from preoperatively to postoperatively in the Neocrom Cohesive, respectively, group and Healon group was +16.0 microm +/- 25.7 (SD) (P<.01) and +7.0 +/- 17.1 microm (P<.05), respectively, at 1 day and -5.7 +/- 10.8 microm (P<.01) and -4.7 microm +/- 9.5 microm) (P<.01), respectively, at 3 months. The mean ECD change at 3 months was 8 +/- 155 cells/mm(2) in the Neocrom Cohesive group (P = .8) and -46 +/- 139 cells/mm(2) in the Healon group (P = .08). The mean IOP increase was +2.2 +/- 3.5 mm Hg (P<.01) and +1.4 +/- 4.2 mm Hg (P = .14), respectively, 6 hours postoperatively and +0.9 +/- 4.3 mm Hg (P = .37) and 0.0 +/- 3.5 mm Hg (P = .77), respectively, at 1 day.
Conclusion: There was no significant difference between Neocrom Cohesive and Healon in the changes in CCT, ECD, and IOP after cataract surgery.
Wust M, Matten P, Nenning M, Findl O Transl Vis Sci Technol. 2022; 11(2):28.
PMID: 35175318 PMC: 8857612. DOI: 10.1167/tvst.11.2.28.
Impact of Ophthalmic Viscosurgical Devices in Cataract Surgery.
Malvankar-Mehta M, Fu A, Subramanian Y, Hutnik C J Ophthalmol. 2020; 2020:7801093.
PMID: 33133677 PMC: 7593745. DOI: 10.1155/2020/7801093.
Hyaluronic Acid: Redefining Its Role.
Abatangelo G, Vindigni V, Avruscio G, Pandis L, Brun P Cells. 2020; 9(7).
PMID: 32708202 PMC: 7409253. DOI: 10.3390/cells9071743.
Hyaluronic Acid-Cellulose Composites as Patches for Minimizing Bacterial Infections.
Lopez K, Ravula S, Perez R, Ayala C, Losso J, Janes M ACS Omega. 2020; 5(8):4125-4132.
PMID: 32149241 PMC: 7057694. DOI: 10.1021/acsomega.9b03852.
Hyaluronic Acid in the Third Millennium.
Fallacara A, Baldini E, Manfredini S, Vertuani S Polymers (Basel). 2019; 10(7).
PMID: 30960626 PMC: 6403654. DOI: 10.3390/polym10070701.